Dr. Wyatt McDonnell is Co-Founder and CEO of Infinimmune, a biotechnology company built on the premise that the human immune system is the best source of therapeutic antibodies. Infinimmune's discovery platform has produced two development candidates—IFX-101 (anti-IL-22) and IFX-201 (anti-IL-13)—and underpins a multi-target antibody discovery collaboration with Merck valued at up to $838 million in milestones. Previously, Wyatt was Technical Lead of Barcode-Enabled Antigen Mapping (BEAM) at 10x Genomics, where he also developed the company's first therapeutic antibodies and core immunology intellectual property behind three commercial products. As a faculty member at Vanderbilt University Medical Center, he studied human immune correlates of chronic viral infection and type 2 diabetes and received Young Investigator awards from CROI, the International Workshop on HIV and Aging, and the American Heart Association. He received his PhD and MSc at Vanderbilt University for his work on T and B cell biology in HIV infection, checkpoint inhibitor toxicity, and other immune-mediated diseases. Wyatt has co-authored 43 peer-reviewed papers in journals including Nature, Cell, and Nature Medicine, and 44 published patents in antibody discovery and engineering, immunobiology, genomics, and in silico antibody models. He has been invited to speak at PEGS, the Keystone Symposia, Antibody Engineering and Therapeutics, the Antibody Series, the World Vaccine Congress, LEAP, PMWC, and Biotech Showcase. He is a one-time National Spelling Bee finalist and can be found playing piano, reading, or exploring the Bay Area culinary scene in his free time.